Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

In Brief

This article was originally published in The Tan Sheet

  • News

Executive Summary

Prestige Brands gains from acquisitions

You may also be interested in...



Prestige Brands’ OTC Revenue Climbs With Boost In Advertising

Prestige CEO Mannelly attributes the success of Clear Eyes, Chloraseptic, Compound W and Little Remedies to a $1 million increase in advertising and promotions. The OTC division’s net revenue soar 55.7% to $79.2 million.

Prestige Brands’ OTC Revenue Climbs With Boost In Advertising

Prestige CEO Mannelly attributes the success of Clear Eyes, Chloraseptic, Compound W and Little Remedies to a $1 million increase in advertising and promotions. The OTC division’s net revenue soar 55.7% to $79.2 million.

In Brief

Abbott Nutrition eyes U.S. launches

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

The People Who Will Shape The UK’s New Drug Pricing Scheme

GSK Makes New Adult Immunization Push, Seeks Reimbursement Changes Following RSV Approvals

Medicare Registry Plan For Alzheimer’s Drugs Pairs CMS Web Portal With Health System Efforts

False Claims Act Liability: Defendant’s Belief Claims Were False Matters, Supreme Court Finds

See All
UsernamePublicRestriction

Register

PS105054

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By